Knowledge management in pharma MCQs With Answer

Knowledge Management in Pharma MCQs With Answer

This quiz compilation is designed for M.Pharm students studying Quality Management Systems (MQA 102T) to deepen understanding of knowledge management (KM) principles applied in the pharmaceutical industry. It focuses on capturing, organizing, sharing and preserving both explicit and tacit knowledge crucial for regulatory compliance, product quality, technology transfer and continuous improvement. Questions cover KM frameworks, tools (ELN, DMS), governance, metrics, cultural barriers, and practical strategies for retaining expert knowledge. Each MCQ is crafted to test conceptual clarity and application in pharma contexts, helping students prepare for exams and real-world responsibilities in knowledge-rich regulated environments.

Q1. What is the most accurate definition of knowledge management (KM) in a pharmaceutical context?

• The process of storing large volumes of raw data from laboratory instruments.
• The systematic process for creating, capturing, organizing, sharing and applying knowledge to achieve organizational objectives such as compliance, innovation and product quality.
• The exclusive use of IT systems to control access to documents and SOPs.
• A regulatory requirement that only addresses document archival for inspections.

Correct Answer: The systematic process for creating, capturing, organizing, sharing and applying knowledge to achieve organizational objectives such as compliance, innovation and product quality.

Q2. Which statement best distinguishes tacit knowledge from explicit knowledge in pharmaceutical operations?

• Tacit knowledge is written in SOPs; explicit knowledge is never documented.
• Tacit knowledge is personal, experiential and hard to formalize, while explicit knowledge is codified, documented and easily shared.
• Explicit knowledge refers only to intellectual property held in patents.
• Tacit knowledge can be shared easily via controlled vocabularies and databases.

Correct Answer: Tacit knowledge is personal, experiential and hard to formalize, while explicit knowledge is codified, documented and easily shared.

Q3. What is the primary strategic goal of implementing KM in a pharmaceutical company?

• Reduce headcount in R&D through automation only.
• Enhance organizational learning to improve product quality, regulatory compliance and innovation while reducing rework and knowledge loss.
• Replace all laboratory staff with knowledge management software.
• Limit information sharing to upper management for competitive reasons.

Correct Answer: Enhance organizational learning to improve product quality, regulatory compliance and innovation while reducing rework and knowledge loss.

Q4. Which sequence correctly represents the core phases of the knowledge lifecycle?

• Retention → Creation → Dissemination → Capture
• Creation → Capture → Organization → Dissemination → Retention
• Dissemination → Creation → Retention → Capture
• Organization → Retention → Creation → Dissemination

Correct Answer: Creation → Capture → Organization → Dissemination → Retention

Q5. Which of the following is NOT typically considered a KM tool in a pharmaceutical quality system?

• Electronic Laboratory Notebook (ELN)
• Document Management System (DMS)
• Community of Practice (CoP) platform
• Chromatography column

Correct Answer: Chromatography column

Q6. What is the primary purpose of conducting a knowledge audit in a pharma organization?

• To perform routine cleaning of document repositories.
• To identify, map and evaluate knowledge assets, flows and critical gaps that affect operations and compliance.
• To measure employee satisfaction unrelated to knowledge sharing.
• To replace SOPs with verbal briefings.

Correct Answer: To identify, map and evaluate knowledge assets, flows and critical gaps that affect operations and compliance.

Q7. How do Standard Operating Procedures (SOPs) function within knowledge management?

• They only serve as legal documents and are not part of KM.
• They codify explicit knowledge and standardize practices, supporting consistent performance and transfer of process knowledge.
• They are intended to replace training programs entirely.
• They are informal notes maintained by individual technicians.

Correct Answer: They codify explicit knowledge and standardize practices, supporting consistent performance and transfer of process knowledge.

Q8. Which organizational barrier most commonly undermines effective knowledge sharing in pharma?

• Excessive investment in collaborative platforms.
• Organizational culture that discourages knowledge sharing due to silos, competition or lack of incentives.
• Having too many training programs.
• Over-documentation of procedures.

Correct Answer: Organizational culture that discourages knowledge sharing due to silos, competition or lack of incentives.

Q9. When a senior process scientist is retiring, which strategy best mitigates loss of their critical tacit knowledge?

• Rely solely on archived emails and reports.
• Conduct structured knowledge elicitation (interviews), mentoring, hands-on shadowing and document the heuristics and decision rules.
• Wait for the successor to rediscover process nuances during scale-up.
• Delete duplicated records to avoid confusion.

Correct Answer: Conduct structured knowledge elicitation (interviews), mentoring, hands-on shadowing and document the heuristics and decision rules.

Q10. Which metric is most appropriate for measuring KM effectiveness in supporting operational decisions?

• Number of printed SOP copies distributed per year.
• Knowledge reuse rate or percentage of decisions supported by documented knowledge leading to reduced investigation time.
• Total storage capacity used by the DMS.
• Number of meetings held to discuss knowledge management.

Correct Answer: Knowledge reuse rate or percentage of decisions supported by documented knowledge leading to reduced investigation time.

Q11. Which statement correctly differentiates data, information and knowledge in the pharmaceutical setting?

• Data is interpreted knowledge, information is raw facts, knowledge is storage format.
• Data are raw facts, information is processed data with context, knowledge is contextualized information enabling decision and action.
• They are interchangeable terms with no distinct roles.
• Knowledge precedes data collection in experiments.

Correct Answer: Data are raw facts, information is processed data with context, knowledge is contextualized information enabling decision and action.

Q12. What is the primary role of a Community of Practice (CoP) in pharma KM?

• To enforce disciplinary action against non-compliant staff.
• To facilitate sharing of tacit knowledge, problem solving, and continuous professional learning across functional boundaries.
• To replace formal training programs completely.
• To centralize all document approval decisions in one person.

Correct Answer: To facilitate sharing of tacit knowledge, problem solving, and continuous professional learning across functional boundaries.

Q13. How does effective KM support regulatory inspections and audit readiness?

• By eliminating the need for corrective actions.
• By ensuring traceable, accessible documented evidence of decisions, training, deviations and process knowledge that demonstrate compliance and robustness.
• By keeping knowledge restricted to senior management only.
• By converting all documents into non-searchable image formats.

Correct Answer: By ensuring traceable, accessible documented evidence of decisions, training, deviations and process knowledge that demonstrate compliance and robustness.

Q14. Which feature is essential when designing a pharmaceutical knowledge repository?

• Lack of metadata to simplify entry
• Robust searchability, controlled vocabulary/taxonomy, metadata and version control
• Only storing final reports without contextual data
• Restricting access to a single team to prevent sharing

Correct Answer: Robust searchability, controlled vocabulary/taxonomy, metadata and version control

Q15. In the Nonaka and Takeuchi SECI model of knowledge creation, what does “Externalization” refer to?

• The conversion of explicit knowledge into tacit knowledge through practice.
• The conversion of tacit knowledge into explicit knowledge, such as articulating insights in documents or models.
• The elimination of redundant documents from the repository.
• The combination of unrelated datasets into one large dataset.

Correct Answer: The conversion of tacit knowledge into explicit knowledge, such as articulating insights in documents or models.

Q16. Which advantage does an Electronic Laboratory Notebook (ELN) provide for KM in pharmaceutical R&D?

• It prevents any editing or annotation of experimental notes.
• Facilitates structured capture of experimental details, searchability, traceability, and reuse of method knowledge.
• Makes paper records obsolete without any audit trail.
• Automatically replaces the need for skilled scientists.

Correct Answer: Facilitates structured capture of experimental details, searchability, traceability, and reuse of method knowledge.

Q17. What legal and IP consideration must KM programs address when promoting cross-site knowledge sharing?

• There are no legal considerations for internal knowledge sharing.
• Implementing access controls, confidentiality agreements (NDAs) and clear IP ownership policies to prevent loss of trade secrets while enabling collaboration.
• Uploading all proprietary know-how to public repositories to accelerate innovation.
• Prohibiting any documentation to avoid IP disputes.

Correct Answer: Implementing access controls, confidentiality agreements (NDAs) and clear IP ownership policies to prevent loss of trade secrets while enabling collaboration.

Q18. Which element is critical for knowledge governance in a pharmaceutical organization?

• Random assignment of document custodians without defined roles.
• Clearly defined roles and responsibilities (knowledge stewards), policies, standards and performance measures for KM.
• Allowing uncontrolled edits by anonymous users.
• Deleting historical records annually to minimize storage costs.

Correct Answer: Clearly defined roles and responsibilities (knowledge stewards), policies, standards and performance measures for KM.

Q19. During technology transfer from development to manufacturing, what risk arises if tacit process knowledge is not effectively transferred?

• Faster scale-up due to fewer constraints.
• Inconsistent product quality, repeated failures or unanticipated deviations due to loss of practical know-how and decision heuristics.
• Lower documentation requirements from regulatory authorities.
• Immediate reduction in production costs without impact.

Correct Answer: Inconsistent product quality, repeated failures or unanticipated deviations due to loss of practical know-how and decision heuristics.

Q20. Which application of artificial intelligence (AI) is most appropriate for KM in pharma?

• Completely replacing human expert judgment in regulatory decisions.
• Enhancing semantic search, automated extraction of insights from unstructured documents and recommendation of relevant knowledge assets to users.
• Automatically destroying redundant knowledge to save space.
• Generating unverified SOPs without human review.

Correct Answer: Enhancing semantic search, automated extraction of insights from unstructured documents and recommendation of relevant knowledge assets to users.

Download